Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Pfizer And BioNTech to Supply U.S. -3-

07/23/2021 | 06:45am EDT

This press release contains "forward-looking statements" of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech's efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential second booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

For a discussion of these and other risks and uncertainties, see BioNTech's Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC's website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Pfizer Contacts:

Media Relations

Amy Rose

+1 (212) 733-7410

https://www.globenewswire.com/Tracker?data=2l6JnfFgd8JQ0kzIUmEbw_HS14u790VSsnbOYl4RDEInOjZxvboq2AZxATLLHYps8MI76BLkKGpBqOl8eiUy6jcwHlD14hOluSIulBXomqk= Amy.Rose@pfizer.com

Investor Relations

Chuck Triano

+1 (212) 733-3901

https://www.globenewswire.com/Tracker?data=k9c9a4kT49o96xV-KecXXgr3Ix_Pv4QC6zZMHHKRnXlX-IZkeVWHEW8sGZw4OQhO-oEKyYG7C33kTXjW2saVeJP8tFwkj72mTwj7pbbaDOogpio-CGb9VwxL9BBiO_lF Charles.E.Triano@Pfizer.com

BioNTech Contacts:

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513

https://www.globenewswire.com/Tracker?data=8wIUbpkMDBff3_3R79dHl-RXWONMOGyHWGuy6spW1c7_5kMQqW2ryWwEJUWoBR7kr0I-iiHMkS3Ob81cPQZzs7S1I7nnUg1HmkCeAjB19S4= Media@biontech.de

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

https://www.globenewswire.com/Tracker?data=SCQB8XD1QIpIhB6kdgsWgsRFNmZPY8k1fwnnjNM6JZjhfkA4zeq4WeexAHUQbQCaMlaz5Qgk06DuXZ4PAapcyKGYmJH4R6r8WAjm8BsbhpI= Investors@biontech.de

(END) Dow Jones Newswires

July 23, 2021 06:45 ET (10:45 GMT)

All news about BIONTECH SE
08:12aMODERNA : U.S. COVID-19 booster debate moves to FDA vaccine advisory committee
07:00aMODERNA : U.S. COVID-19 booster debate moves to FDA vaccine advisory committee
02:24aPFIZER : Hong Kong Assesses Pfizer-BioNTech's COVID-19 Jab In Booster Study
09/16Pfizer-BioNTech, Moderna's Booster COVID-19 Shots Enters Real-Time Review in ..
09/16UK Study to Mix Three COVID-19 Vaccine Doses in Adolescents
09/16PFIZER : CEO Backs Booster Shots Ahead of FDA Committee Meeting
09/16PFIZER : and BioNTech Covid Vaccine Gets Approval From Health Canada for Individ..
09/16PFIZER : FDA Sees Current COVID-19 Vaccine Protocol as Still Effective Ahead of ..
09/16PFIZER : FDA Says Currently Authorized COVID-19 Vaccines in the US Remain Effect..
09/16Singapore Sees Lowest Unemployment Rate Since March 2020 in Q2; Job Vacancies..
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Sales 2021 16 863 M 19 855 M 19 855 M
Net income 2021 8 881 M 10 456 M 10 456 M
Net cash 2021 9 100 M 10 715 M 10 715 M
P/E ratio 2021 8,93x
Yield 2021 -
Capitalization 76 502 M 90 003 M 90 078 M
EV / Sales 2021 4,00x
EV / Sales 2022 3,25x
Nbr of Employees 2 500
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Last Close Price 316,75 €
Average target price 279,31 €
Spread / Average Target -11,8%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE357.13%90 003
WUXI APPTEC CO., LTD.28.41%65 728
BEIGENE, LTD.49.09%35 842